S978 A Nationwide Comparison of Risankizumab-rzaa, Vedolizumab, and Adalimumab on Infection and Neuromusculoskeletal Adverse Events in Crohn’s Disease Patients: A Pharmacovigilance Investigation
American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S737-S738
10.14309/01.ajg.0000953552.34551.44